Background {#Sec1}
==========

Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer \[[@CR1]\]. Due to its unclear pathogenesis and lack of early detection method, about 75% of EOC patients have advanced-stage at initial diagnosis, and the effect of treatment and prognosis are both not good. Therefore, further exploration of the mechanism of EOC onset and later peritoneal metastasis is of great significance for finding new earlier diagnostic biomarkers and new target of blocking tumor metastasis.

In modern tumor biology, it is well known that tumor microenvironment is a key factor in malignant tumor development and metastasis. Moreover, studies have shown that the tumor-associated inflammatory microenvironment constructed by a variety of inflammatory factors secreted by tumors and stromal cells (such as fibroblasts), regulates the growth, invasion and metastasis of tumor cells, and ultimately directly determine the malignant properties of tumor cells \[[@CR2]--[@CR6]\]. It is reported that the inflammatory response involved in the pathogenesis of ovarian cancer, for the malignant ascites containing a large number of exfoliated cancerous cells, which may become a source of cancer cells metastasis and peritoneal implantation \[[@CR7]--[@CR9]\]; high concentrations of pro-inflammatory cytokines such as IL-6, IL-8 contained in ascites can promote cancer cell growth and metastasis, which all can accelerate the progress of the disease, reducing the treatment effect and worsening the prognosis \[[@CR10]--[@CR12]\]. However, with further research, some other factors should be found to be more decisive in the formation and maintain of inflammatory microenvironment, and might play very important role in tumor growth by promoting secretion of some inflammatory cytokines.

Cyr61 (cysteine-rich protein 61) is the first identified member of the CCN family, also known as CCN1. It is a 40 kDa secreted matrix protein and is known to play an important role in cell proliferation, adhesion, inducing angiogenesis and other important physiological activities \[[@CR13]--[@CR16]\]. Moreover, Cyr61 has been reported recently to participate in tumor development, promoting vascular proliferation or increasing tumor cell proliferation and migration \[[@CR17]--[@CR19]\]. What's more, Cyr61 may mainly promote secretion of IL-6, IL-8, pro-IL-1β et al. to enhancing inflammation and tissue damage as a novel pro-inflammatory cytokine \[[@CR20]--[@CR24]\]. In human tumor inflammatory microenvironment, IL-6 has also been proved to stimulate the migration and invasion of cancer cells of breast cancer, pancreatic cancer and osteosarcoma \[[@CR25]--[@CR27]\]. Similarly, some studies about ovarian cancer have found that IL-6 also promotes the development of tumor, which is closely related to the prognosis \[[@CR28], [@CR29]\]. So Cyr61 may be a protagonist in tumor inflammatory microenvironment.

For ovaries, there is a dynamic inflammatory reaction in each ovulation cycle. And recent studies have shown that the incidence of ovarian cancer is closely related to the wound repair caused by continuous ovulation. So it is of great significance to explore the inflammatory response involved in the formation and maintain of ovarian cancer microenvironment for the early diagnosis and appropriate treatment. Nevertheless, whether Cyr61 plays a pivotal role in the inflammation microenvironment processes of ovarian carcinoma development has not been explored yet. In this study, the Cyr61 expression patterns in serum, ascites and tissue of EOC were evaluated. At the same time, the correlation of Cyr61 with IL-6, other inflammatory markers and clinicopathologic features was analyzed respectively to explore the potential association of Cyr61with EOC progression in the tumor-associated inflammatory response.

Methods {#Sec2}
=======

Patient samples {#Sec3}
---------------

Between January 2014 and December 2016, tumor tissue, ascites (or peritoneal lavage fluid) and peripheral blood samples were obtained from 66 patients with ovarian serous cystadenocarcinoma (mean age: 58.24 ± 0.99 years) and 18 patients with ovarian serous cystadenoma (mean age: 43.06 ± 2.16 years) of the Department of and Obstetrics and Gynecology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.

Two experienced pathologists reviewed the paraffin pathology respectively. Stage is based on the 2014 International Federation of Gynecology and Obstetrics (FIGO) criteria. The exclusion criteria were inadequate follow-up data, chemotherapy before operation and combined with inflammatory or immune disease. Ascites fluid was obtained at the time of initial surgery and centrifuged at 1000 g for 15 min. The peripheral blood samples were taken on the morning before the operation. Ascites supernatants and all serum samples were stored at − 80 °C until assayed. Tissue specimens were snap-frozen in liquid nitrogen.

This study was approved by ethics committee of Renji Hospital, School of Medicine, Shanghai Jiao Tong University and it was in compliance with the Helsinki Declaration. All the patients gave written informed consent for participation in the study.

Enzyme linked Immunosorbent assay (ELISA) {#Sec4}
-----------------------------------------

ELISA kit (Cyr61, Cat Log\#: DY4055; IL-6, Cat Log\#: HS600B; R&D System, MN, USA) for quantitatively detecting serum and ascites of Cyr61, IL-6 were used according to the manufacturer's instructions. Briefly, the samples were added in duplicate to the wells of the microtiter plate coated with an antibody against Cyr61 or IL-6 with horseradish peroxidase-conjugate. Then, absorbance at the 450 nm in each microwell was measured using spectrophotometer. Each cytokine analysis was simultaneously performed on all patients and control serum, thereby avoiding a possible defrosting/refreezing bias.

Laboratory analyses {#Sec5}
-------------------

Laboratory data were obtained from medical records; Blood samples were originally taken using standard procedures and analyzed in the course of routine treatment. Blood routine examination was quantified by Sysmex kit. C-reactive protein (CRP) was quantified by Aristo (AR51200) kit.

Immunohistochemical (IHC) stain and data analysis {#Sec6}
-------------------------------------------------

Ovarian serous cystadenoma and serous cystadenocarcinoma tissues were fixed in 4% paraformaldehyde, embedded in paraffin and sectioned. The Cyr61 expression was determined by immunohistochemistry assay. Briefly, the tissue samples were stained with mouse anti-human Cyr61 mAb at a concentration of 1:200 followed by HRP conjugated goat anti-mouse secondary antibody according to previous reports \[[@CR30], [@CR31]\]. Cyr61 expression evaluated by two independent observers though examining the Cyr61-stained tissue, and a consensus score was determined for each specimen.

A positive reaction was scored into 4 grades, according to the intensity of the staining: 0, +, ++, and +++. The percentages of Cyr61-positive cells were also scored into 5 categories: 0 (≤5%), 1 (6--25%), 2 (26--50%), 3 (51--75%) and 4 (76--100%). The final score, calculated as the product of the intensity score multiplied by the percentage score, was classified as follows: 0 for negative; 1--3 for weak; 4--7 for moderate; and 8--12 for strong.

Statistical analysis {#Sec7}
--------------------

Data were presented as mean ± SD or n (%), differences between groups were analyzed by unpaired Student's t test. Comparisons of categorical variables were conducted using x^2^ testing. For all statistical analyses, 2-tailed *P* \< 0.05 was considered statistically significant. All statistical analyses were performed using the Statistical Package for the Social Sciences, version 13.0 (SPSS Inc., Chicago, IL, USA) or GraphPad Prism 4.0 (GraphPad Software, San Diego, CA).

Results {#Sec8}
=======

Higher Cyr61 level was found in ascites than in serum of ovarian serous cystadenocarcinoma {#Sec9}
------------------------------------------------------------------------------------------

Both in ascites and serum, significantly higher Cyr61 levels were found in the malignant ovarian tumor (Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Expression levels of Cyr61 in ascites and serum of ovarian benign and malignant tumor *Cyr61 levels in ascites and serum of ovarian serous adenocarcinoma patients (n = 66) were significantly higher than those of ovarian serous cystadenoma patients (n = 18). And the ascites Cyr61 level was much higher than that of serum*

In ascites, the Cyr61 level of ovarian serous cystadenocarcinoma (*n* = 66) and serous cystadenoma (*n* = 18) was 1624.33 ± 191.92 cf. 230.11 ± 25.63 pg/ml respectively (*p* \< 0.001); in serum, the Cyr61 level was 77.21 ± 4.81 cf. 13.32 ± 3.14 pg/ml, correspondingly (*p* \< 0.001).

Moreover, the same patient with ovarian serous cystadenocarcinoma, ascites of Cyr61 level was much higher than its serum level.

High ascites Cyr61 level associated with clinicopathologic features of ovarian serous cystadenocarcinoma {#Sec10}
--------------------------------------------------------------------------------------------------------

Tumor ascites microenvironment may reflect the tumor characteristics and its progress. So ascites Cyr61 was analyzed to clear its relationships with the clinicopathologic features of ovarian serous cystadenocarcinoma. Multiple regression analysis showed that.

Ascites Cyr61 level was more closely associated with FIGO stage (*p* = 0.001), initial tumor size \> 10 cm (*p* = 0.002) and the residual tumor size (*p* = 0.025). But there was no correlation with the tumor histological grade (*p* = 0.539), total ascites volume (*p* = 0.124), ascites contains tumor cells (*p* = 0.124), vascular invasion (*p* = 1.756) and lymph node metastasis (*p* = 1.475) (Table [1](#Tab1){ref-type="table"}). Table 1Correlation of the clinicopathologic features and ascites Cyr61 level of ovarian serous adenocarcinomaClinicopathologic factorsCategorizationNumber (%)Cyr61 (pg/ml)*P* valueFIGO stageI-II14 (21.1)698.74 ± 87.120.001III-IV52 (78.9)2054.23 ± 132.09^\*^Initial tumor size (cm)\< 1045 (68.2)910.81 ± 98.310.002≥1021 (31.8)2125.66 ± 154.38^\*^Ascites volume (ml)\< 5009 (13.6)1416.41 ± 102.370.124≥50057 (86.4)1760.65 ± 154.64Residual tumor (cm)\< 154 (81.8)1031.64 ± 78.310.025≥112 (18.2)2097.30 ± 174.69^\*^Lymphatic invasion--60 (90.9)1936.22 ± 191.371.475+6 (9.1)2128.37 ± 478.26Vascular invasion--62 (93.9)2117.11 ± 201.391.756+4 (6.1)2403.74 ± 345.21Ascites tumor cells--57 (86.4)1613.62 ± 119.270.124+9 (13.6)1736.28 ± 114.30

High ascites IL-6 level is associated with Cyr61 in the inflammatory microenvironment of ovarian serous cystadenocarcinoma {#Sec11}
--------------------------------------------------------------------------------------------------------------------------

As a new pro-inflammatory factor, Cyr61 can regulate the expression of cytokines in inflammatory environment and it was correlated with tumor stage. So the ascites Cyr61 and IL-6 levels of ovarian serous cystadenocarcinoma were detected, respectively.

Ascites Cyr61 and IL-6 levels of advanced stage were (2199.86 ± 116.24 pg/ml, 3227.42 ± 147.82 pg/ml) both higher than those of early stage (778.98 ± 47.25 pg/ml, 1422.32 ± 74.69 pg/ml) (Fig. [2A](#Fig2){ref-type="fig"}). Fig. 2Cyr61 and IL-6 levels in ascites of different (the early or advanced) stage of ovarian cancer patient and the correlation. *In the patient with ovarian serous adenocarcinoma, ascites Cyr61 and IL-6 levels of the advanced stage (n = 52) were both higher than those of the early stage (n = 14). And the increased IL-6 expression was linearly related to Cyr61 level in malignant ascites*

And the increase of IL-6 level in ascites was linearly related to Cyr61 level (Fig. [2B](#Fig2){ref-type="fig"}).

Expressions of serum Cyr61 and inflammatory markers in different stages of ovarian cancer {#Sec12}
-----------------------------------------------------------------------------------------

Inflammation is a reaction in the process of tumor development. We further examined the expression patterns of Cyr61, IL-6, CRP and neutrophil percentage in peripheral blood of patient with early or advanced stage of ovarian serous cystadenocarcinoma.

In addition to Cyr61 and IL-6, CRP serum level in advanced ovarian cancer was significantly higher than those in the early stage. However, the proportion of neutrophils of the advanced stage patients was a little higher than that in early stage, but there was no statistical difference (Table [2](#Tab2){ref-type="table"}). Table 2Inflammatory markers in peripheral blood of ovarian cancer patient with different stagesStageCyr61 (pg/ml)IL-6 (pg/ml)CRP (mg/L)Neutrophils (%)Early stage52.55 ± 13.9367.23 ± 17.437.77 ± 1.1067.45 ± 2.37Advanced stage120.76 ± 22.35212.47 ± 40.2723.18 ± 4.4873.56 ± 2.21P value0.0310.0150.0041.247

Cyr61 expression patterns in ovarian serous tumor {#Sec13}
-------------------------------------------------

18 cases of ovarian serous cystadenoma, 66 cases of ovarian serous adenocarcinoma and 20 cases of its paired metastatic lesions were evaluated using IHC to confirm Cyr61expression patterns in ovarian caner (Fig. [3](#Fig3){ref-type="fig"} and Table [3](#Tab3){ref-type="table"}). Fig. 3Cyr61 expression patterns in the different tissues of ovarian tumor by immunohistochemistry. **a** *Benign ovarian cyst* (*ovarian serous cystadenoma) showed weak Cyr61 expression.* **b** *High grade of ovarian serous adenocarcinoma showed moderate degree Cyr61 expression.* **c** and **d** *High grade of ovarian serous adenocarcinoma of the same patient of primary and paired metastatic site showed the moderate and strong degree Cyr61 expression, respectively* Table 3Correlation of the pathological features and Cyr61 expression positive ratePathological typeCyr61 expressionNegative (0)Weak (1--3)Moderate (4--7)Strong (8--12)Positive rateOvarian serous cystadenoma (n = 18)98105.56Ovarian serous adenocarcinoma (n = 66)G1/G2 (*n* = 7)034057.14\*\*G3 (*n* = 59)06381589.83\*\*Paired Metastatic site (*n* = 20)0011995.00\*Positive rate: including moderate and strong of the intensity score (≥4)\*\*: Ovarian serous cystadenoma cf. Ovarian serous adenocarcinoma (*p* \< 0.01);\*: Paired Metastatic site cf. Ovarian serous adenocarcinoma (*p* \< 0.05)

Cyr61 expression positive rate (≥4 scores) of ovarian serous cystadenoma was significantly lower than the ovarian cancer (*p* \< 0.01). Further, the positive rate of its paired metastatic lesions of was higher than the primary adenocarcinoma (*p* \< 0.05).

Discussion {#Sec14}
==========

The latest research results showed that there were six characteristics of the pre-metastasis microenvironment including immunosuppression, inflammatory response, enhanced angiogenesis and permeability, lymphangiogenesis, organotropy and reprogramming. It indeed indicated that the inflammatory reaction was an indispensable part of tumor progress \[[@CR32]\]. Further, recent studies have confirmed that inflammatory microenvironment is an essential environment for tumor cells survive. In the inflammatory microenvironment, different extracellular matrix, inflammatory factors and stromal cells interact with tumor cells to promote tumor proliferation and metastasis \[[@CR33]--[@CR37]\]. The malignant ascites of ovarian cancer is a huge tumor microenvironment with its complex composition, which can enhance the ability of tumor to deteriorate \[[@CR38]--[@CR40]\].

Since previous studies have shown that the incidence of ovarian cancer is closely related to periodic ovulation and the continuous repair of ovarian surface tissues damage, it was found that the inflammatory microenvironment had a direct regulatory effect on ovarian cancer development. For various inflammatory reactions are accompanied with the process of the ovulation, all sorts of secreted cytokines and chemokine may form the microenvironment together, and it can promote the activation of oncogenes and cell carcinogenesis. So it can reveal the early events of ovarian cancer and the biological characteristics of the tumor cells. On the other hand, to be an ovarian cancer cell, it is also affected daily by physiological cycle and corresponding inflammatory changes, accelerating tumor progression. Therefore, the inflammatory microenvironment is essential for ovarian cancer \[[@CR41]--[@CR44]\].

As a novel pro-inflammatory factor, Cyr61 has been found to paly a key promoter to maintain the inflammatory microenvironment in some inflammatory and autoimmune diseases. Recently, it is interesting that "interstitium" is found to be one of the largest human organs. It is linked together to form a network supported by a strong, flexible protein network, filled with fluids in the human body. As a "highway", full of the flowing fluids in the body, "interstitum" may help cancer cells metastasis \[[@CR45]\]. Therefore, as one of the important interstitial proteins, Cyr61might act as a mediator in the inflammatory microenvironment of tumor. In order to analyze the role of Cyr61 play in the inflammatory microenvironment of ovarian cancer, we detected the Cyr61 level in ascites and serum of patients with ovarian serous adenocarcinoma. The Cyr61 level not only in ascites but also in serum of ovarian serous adenocarcinoma was higher than that of ovarian serous cystadenoma.

What's more, about ovarian serous adenocarcinoma, Cyr61 level of ascites was higher than that of serum, which fully demonstrated that Cyr61 might be one of the important components in malignant ascites. And multiple regression analysis showed that Cyr61 level in ascites of ovarian serous adenocarcinoma only related to the initial tumor size, FIGO stage and surgical residual tumor size, which indicates that the increased Cyr61 level closely associated with tumor proliferation and metastasis. Further, IHC was used to analyze the expression of Cyr61 in ovarian serous adenocarcinoma tissues at different stages of progression. The results showed that the Cyr61 expression of metastatic tumor lesions (peritoneal foci) was higher than that of the primary lesions, which may signify Cyr61 playing a vital role in peritoneal metastasis.

As it is well known that IL-6 acts as promoter of tumor development and metastasis by composing inflammatory environment \[[@CR46], [@CR47]\]. To be the up-stream factor, Cyr61 was reported that it really promoted IL-6 secretion in the microenvironment of some inflammatory and autoimmune diseases. To explore the hypothesis that Cyr61 might also promote IL-6 production by tumor cells, then together with other factors, forming a tumor-associated inflammatory microenvironment to promote tumorigenesis, we examined the IL-6 level of ascites in ovarian serous adenocarcinoma patients and analyzed its correlation with Cyr61. The results showed that the levels of Cyr61 and IL-6 in advanced stage were significantly higher than those in early stage, which indicated that the later of the disease, the higher of Cyr61 and IL-6 levels. Further analysis showed that elevated level of IL-6 was positively correlated with elevated Cyr61 level, suggesting a synergistic effect between them in the development of tumor inflammation microenvironment.

Latest research suggested that there must be a series of special inflammatory response during the initial stage of the human tumor. Clinically, there are some commonly used biomarkers in the body's inflammatory response, for example, white blood cells, neutrophils, CRP \[[@CR48]\] and so on. Among them, neutrophils are the earliest to reach the site of inflammatory response \[[@CR49]\]. It is very interesting that Cyr61 (early event) could recruit neutrophils to target sites by up-regulation IL-8 production by tissue cells at the site of inflammation. However, whether Cyr61 can mediate cytokines production and neutrophil infiltration in tumor tissues cells has not been reported yet. So we analyzed the changes of Cyr61, CRP and the percentage neutrophils in the peripheral blood of ovarian tumor. In addition to Cyr61 and IL-6, CRP serum level in advanced ovarian serous adenocarcinoma was significantly higher than those in early stage, but there was no correlation with Cyr61level. And the increasing trend of the proportion neutrophils was consistent with that of Cyr61 level. The higher level of Cyr61was, the higher percentage neutrophils became. Thus it can be seen that Cyr61may mediate neutrophil infiltration and CRP product in advanced ovarian serous adenocarcinoma just like it acts in the inflammation or autoimmune diseases. However, the specific signaling pathway remains to be studied in the near future.

Conclusion {#Sec15}
==========

Our study has systematically analyzed the important role of Cyr61 as a tumor related inflammatory factor in promoting the development of ovarian cancer microenvironment.

As a pro-inflammatory matrix protein, Cyr61 expression is increasing in ovarian serous adenocarcinoma, increasing in the advanced stage, and increasing in its metastatic tumor, which suggested that Cyr61 is closely associated with the development and metastasis of EOC. More importantly, Cyr61 may paly regulation action in the upstream for tumor inflammatory microenvironment formation and maintain, especially for IL-6 expression. And as a new tumor associated inflammatory marker, Cyr61 might be a potential target and biomarker in the diagnosis, treatment and prediction of EOC, but it needs to be further study.
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